The field of oncolytic viruses was quite dormant in the first decade of the 2000s, characterized by slow clinical progress due to hypercautiousness and low, albeit steady, investments. The takeover of BioVex by Amgen in late 2011, worth up to US$ 1 bln, has woken up the field and became a game changer together with the 2015 approval of the first oncolytic virus Imlygic developed by BioVex in regulated markets. In addition, it was increasingly recognized that oncolytic viruses not only were able to directly lyse cancer cells, but they also 鈥瀎reed鈥� tumor specific neoantigens, indirectly acting as a cancer vaccine.
However, the efficacy of oncolytic viruses still was modest, but can be improved when combined with immune checkpoint inhibitors. This lead to an increased partnering interest of the major immuno-oncology (I-O) players, but also of investors who view oncolytic viruses as a must be for I-O combination regimens. As a consequence, total venture equity and private investments into oncolytic virus companies in 2016 was nearly 17-fold higher than in the year 2010.
Optimization of oncolytic viruses is ongoing and new constructs intend to solve some of the open problems regarding the way of administration (intratumoral vs systemic), higher cancer cell specific replication capacity, and longer persistence in vivo. Based on experience with several virus families over the last decades, a few virus families cristallized as well suitable backbones to carry more and more transgenes to express proteins or even single chain antibodies. This would position oncolytic viruses as independent therapeutics and could compete with immuno-oncology compounds and cancer vaccines.
This report 鈥�The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities鈥� as of January 2017 brings you up-to-date regarding key players, key technologies, Oncolytic Virus projects, business deals and private and public financing rounds. The report analyzes the Oncolytic Virus pipeline and stakeholders in the field, especially among Big Pharma/Biotech and technology companies. The report highlights the value of oncolytic viruses in terms of partnering terms and conditions, venture and private financing and (initial) public offerings.
This report has been built in a bottom-up way by desktop search to identify and describe company, product, technology and business/financing profiles which then were evaluated and analyzed with a final outlook describing perspectives with challenges and opportunities.
What will you find in the report?
Who will benefit from the report?
Table of Contents
1听听听听听听听听听 Executive Summary
2听听听听听听听听听 Introduction & Overview
3听听听听听听听听听 Selection, Design & Construction of Oncolytic Viruses
3.1听听听听听听 Herpes Simplex Virus (HSV) 鈥� based Oncolytic Viruses
3.2听听听听听听 Adenoviruses 鈥� based Oncolytic Viruses
3.3听听听听听听 Vaccinia Virus - Based Oncolytic Viruses
3.4听听听听听听 Vesicular Stomatitis Virus - based Oncolytic Viruses
3.5听听听听听听 Newcastle Disease Virus - based Oncolytic Viruses
3.6听听听听听听 Various Oncolytic Viruses
4听听听听听听听听听 Profiles of Oncolytic Viruses
4.1听听听听听听 HSV-based Oncolytic Viruses
4.1.1听听听 Imlygic; talimogene laherparepvec; T-Vec; OncoVEX(GM-CSF)
4.1.2听听听 G47螖
4.1.3听听听 HF10; TB-1401
4.1.4听听听 HSV1716; seprehvir
4.1.5听听听 HSV-Rb-p450
4.1.6听听听 BV-2711
4.1.7听听听 ONCR-001
4.2听听听听听听 Adenovirus-based Oncolytic Viruses
4.2.1听听听 Oncorine
4.2.2听听听 CG0070
4.2.3听听听 DNX-2401
4.2.4听听听 OBP-301; telomelysin
4.2.5听听听 ONCOS-102
4.2.6听听听 Enadenotucirev; ColoAd1
4.2.7听听听 Adenoviral VirRx 007; INGN 007; VRX-007
4.2.8听听听 VCN-01
4.2.9听听听 LOAd703
4.2.10听 H103
4.2.11听 NG-348
4.2.12听 ORCA-010
4.2.13听 TILT-123
4.2.14听 UIO-112
4.2.15听 TILT-324
4.2.16听 DNX-2440; Delta-24-RGDOX
4.2.17听 DNX-2450
4.2.18听 OBP-702
4.3听听听听听听 Vaccinia Virus-based Oncolytic Viruses
4.3.1听听听 Pexastimogene devacirepvec; Pexa-Vec; JX-594; TG6006
4.3.2听听听 GL-ONC1
4.3.3听听听 JX-929; vvDD
4.3.4听听听 TG6002
4.3.5听听听 WO-12
4.4听听听听听听 Vesicular Stomatitis Virus-based Oncolytic Viruses
4.4.1听听听 MG1 Maraba/MAGE-A3 (MG1MA3)
4.4.2听听听 VSV-IFNbeta
4.4.3听听听 VSV-IFNbeta-NIS
4.4.4听听听 VSV-GP
4.5听听听听听听 Newcastle Disease Virus-based Oncolytic Viruses
4.5.1听听听 NDV-HUJ
4.5.2听听听 PV701
4.5.3听听听 recNDVGM-CSF
4.6听听听听听听 Various Oncolytic Viruses
4.6.1听听听 Rigvir
4.6.2听听听 Reolysin; pelareorep
4.6.3听听听 CAVATAK; CVA21
4.6.4听听听 MV-NIS
4.6.5听听听 NTX-010; SVV-001
4.6.6听听听 H-1PV
4.6.7听听听 PVS-RIPO
4.6.8听听听 MYX-135
4.7听听听听听听 Stem Cell-delivered Oncolytic Viruses
4.7.1听听听 TBX.OncV (CRad-Survivan-pk7)
4.7.2听听听 MSC-ICOVIR-5
5听听听听听听听听听 Analysis of Oncolytic Virus Pipeline
5.1听听听听听听 Overview of the Pipeline of Oncolytic Viruses
5.2听听听听听听 Approved and 麻豆原创ed Oncolytic Viruses
5.3听听听听听听 Late Stage Development of Oncolytic Viruses
5.4听听听听听听 Combination of Oncolytic Viruses with Immune Checkpoint Inhibitors and Other Anti-Tumor Agents
5.5听听听听听听 Armed Oncolytic Viruses
6 Company Profiles
6.1听听听听听听 Pharma & Biotech
6.1.1听听听 Amgen
6.1.2听听听 Astellas Pharma
6.1.3听听听 AstraZeneca
6.1.4听听听 Boehringer Ingelheim
6.1.5听听听 Bristol-Myers Squibb
6.1.6听听听 Celgene
6.1.7听听听 Daiichi Sankyo
6.1.8听听听 Green Cross
6.1.9听听听 Jiangsu Hengrui
6.1.10听 Lee Pharma
6.1.11听 Medigen Biotechnology
6.1.12听 Merck
6.1.13听 Otsuka Pharmaceutical Co
6.1.14听 Pfizer
6.1.15听 Roche
6.2听听听听听听 First Generation Oncolytic Virus Companies
6.2.1听听听 Cold Genesys
6.2.2听听听 Genelux
6.2.3听听听 Latima
6.2.4听听听 Multivir / VirRx
6.2.5听听听 Neotropix
6.2.6听听听 Oncolytics Biotech
6.2.7听听听 Shanghai Sunway Biotech
6.2.8听听听 SillaJen
6.2.9听听听 Takara Bio
6.2.10听 Theravir
6.2.11听 Virttu Biologics & TNK Therapeutics
6.2.12听 Wellstat Biologics
6.3听听听听听听 Second Generation Oncolytic Virus Companies
6.3.1听听听 DNAtrix
6.3.2听听听 Oncolys BioPharma
6.3.3听听听 ORCA Therapeutics
6.3.4听听听 Oryx
6.3.5听听听 Targovax
6.3.6听听听 VCN Biosciences
6.3.7听听听 Viralytics
6.4听听听听听听 Third Generation Oncolytic Virus Companies
6.4.1听听听 Benevir BioPharm
6.4.2听听听 Lokon Pharma
6.4.3听听听 PsiOxus Therapeutics
6.4.4听听听 Transgene
6.5听听听听听听 Fourth Generation Oncolytic Virus Companies
6.5.1听听听 Duke University Start-Up Company
6.5.2听听听 IGNITE Immunotherapy
6.5.3听听听 Oncorus
6.5.4听听听 Replimmune
6.5.5听听听 TILT Biotherapeutics
6.5.6听听听 Turnstone Biologics
6.5.7听听听 Unleash Immuno Oncolytics
6.5.8听听听 ViraTherapeutics
6.5.9听听听 Vyriad
6.5.10听 Western Oncolytics
7听听听听听听听听听 Stakeholder Analysis
7.1听听听听听听 Pharma & Biotech
7.2听听听听听听 First Generation Oncolytic Virus Companies
7.3听听听听听听 Second Generation Oncolytic Virus Companies
7.4听听听听听听 Third Generation Oncolytic Virus Companies
7.5听听听听听听 Fourth Generation Oncolytic Virus Companies
8听听听听听听听听听 Financing & Partnering
8.1听听听听听听 Grants, Credits & Donations
8.2听听听听听听 Venture Capital, Private Equity & Private Placements
8.3听听听听听听 Partnering Deals
8.4听听听听听听 Listing on the Stock 麻豆原创
8.5听听听听听听 Mergers & Acquisitions
9听听听听听听听听听 Trends & Opportunities
10听听听听听听听 References
Tables in the Text:
Table 1: Selection, Design & Construction of HSV - based Oncolytic Viruses
Table 2: Selection, Design & Construction of Adenovirus - based Oncolytic Viruses
Table 3: Selection, Design & Construction of Vaccinia Virus - based Oncolytic Viruses
Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses
Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses
Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses
Table 7: Current Company-Sponsored Clinical Trials of T-Vec
Table 8: Clinical Trials of ColoAd1听
Table 9: Clinical Trials with JX-594
Table 10: Clinical Trials with GL-ONC1
Table 11: Clinical Trials of CAVATAK (CVA21)
Table 12: Clinical Trials with MV-NIS
Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family
Table 14: Profile of Approved and 麻豆原创ed Oncolytic Viruses
Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results
Table 16: Approved Indications of Immune Checkpoint Inhibitors听
Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI)
Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI)
Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics
Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase
Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and/or Positive Completed Clinical Studies
Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses
Table 23: Immuno-Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses
Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses
Table 25: First Generation Oncology Virus Companies and their Sources of Technology
Table 26: Second Generation Oncology Virus Companies and their Sources of Technology
Table 27: Third Generation Oncology Virus Companies and their Sources of Technology
Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology
Table 29: Grants, Credits & Donations
Table 30: Financing by Venture Capital, Private Equity and Other Private Placements
Table 31: Collaboration & Licensing Agreements
Table 32: Companies Listed on Stock Exchange & Offerings
Table 33: Mergers & Acquisitions
Companies mentioned in the report
Amgen
Astellas Pharma
AstraZeneca (MedImmune)
Bayer
Benevir Biopharm
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Cold Genesys
Daiichi Sankyo
DNAtrix
Duke University start-up Company
GeneLux
Green Cross
Grifols
GSK (GlaxoSmithKline)
IGNITE Immunotherapy
Jiangsu Hengrui
Latima
Lee鈥檚 Pharma
Lokon Pharma
Medigen Biotechnology
Merck
Multivir
Neotropix
Oncolys BioPharma
Oncolytics Biotech
Oncorus
Orca Therapeutics
Oryx
Otsuka Pharmaceutical Co
Pfizer
Profectus Biosciences
PsiOxus
Replimune
Roche
Shanghai Sunway Biotech
SillaJen
Sotio
StemImmune
StingInn
Takara Bio
Targovax
TheraBiologics
Theravir
TILT听 Biotherapeutics
Transgene
Turnstone Biologics
Unleash Immuno Oncolytics
VCN Biosciences
Viralytics
ViraTherapeutics
Virttu Biologics (TNK Therapeutics)
Vyriad
Wellstat Biologics
Western Oncolytics
听
听
*If Applicable.